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Abstract
Background: Current cancer immunotherapies have made tremendous impacts but generally lack high response
rates, especially in ovarian cancer. New therapies are needed to provide increased benefits. One understudied
approach is to target the large population of immunosuppressive tumor-associated macrophages (TAMs). Using
inducible transgenic mice, we recently reported that upregulating nuclear factor-kappaB (NF-κB) signaling in TAMs
promotes the M1, anti-tumor phenotype and limits ovarian cancer progression. We also developed a mannose-decorated polymeric nanoparticle system (MnNPs) to preferentially deliver siRNA payloads to M2, pro-tumor macrophages
in vitro. In this study, we tested a translational strategy to repolarize ovarian TAMs via MnNPs loaded with siRNA targeting the inhibitor of NF-κB alpha (IκBα) using mouse models of ovarian cancer.
Methods: We evaluated treatment with MnNPs loaded with IκBα siRNA (IκBα-MnNPs) or scrambled siRNA in syngeneic ovarian cancer models. ID8 tumors in C57Bl/6 mice were used to evaluate consecutive-day treatment of
late-stage disease while TBR5 tumors in FVB mice were used to evaluate repetitive treatments in a faster-developing
disease model. MnNPs were evaluated for biodistribution and therapeutic efficacy in both models.
Results: Stimulation of NF-κB activity and repolarization to an M1 phenotype via IκBα-MnNP treatment was confirmed using cultured luciferase-reporter macrophages. Delivery of MnNPs with fluorescent payloads (Cy5-MnNPs) to
macrophages in the solid tumors and ascites was confirmed in both tumor models. A three consecutive-day treatment of IκBα-MnNPs in the ID8 model validated a shift towards M1 macrophage polarization in vivo. A clear therapeutic effect was observed with biweekly treatments over 2-3 weeks in the TBR5 model where significantly reduced
tumor burden was accompanied by changes in immune cell composition, indicative of reduced immunosuppressive
tumor microenvironment. No evidence of toxicity associated with MnNP treatment was observed in either model.
Conclusions: In mouse models of ovarian cancer, MnNPs were preferentially associated with macrophages in ascites
fluid and solid tumors. Evidence of macrophage repolarization, increased inflammatory cues, and reduced tumor
burden in IκBα-MnNP-treated mice indicate beneficial outcomes in models of established disease. We have provided
evidence of a targeted, TAM-directed approach to increase anti-tumor immunity in ovarian cancer with strong translational potential for future clinical studies.
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Background
The use of cancer immunotherapies, including immune
checkpoint blockades (ICBs), is rapidly expanding as
a result of early successes in clinical trials. Multiple
clinical trials have resulted in FDA-approved treatments for a variety of cancers, including melanoma [1,
2], non-small cell lung cancer [3], urothelial cancer [4,
5], renal cell carcinoma [6], colorectal cancer [7], and
triple-negative breast cancer (TNBC) [8], among others
reviewed here [9]. While ICBs represent an important
advancement in cancer therapy, disappointingly low
overall response rates (ORRs) are commonly observed.
In particular, clinical trials involving the treatment of
epithelial ovarian cancer resulted in ORRs of 15 and 8%
for monotherapies of nivolumab and pembrolizumab,
respectively [10–12]. Epithelial ovarian cancer (EOC)
is estimated to be the fifth leading cause of cancerrelated deaths in females in the U.S. and is in desperate need of improved therapies [13]. The relatively late
presentation of disease in most patients contributes to
overall survival of 40% at diagnosis [14]. The primary
standard of care (surgery followed by platinum- and
taxane-based chemotherapy) is initially effective in over
70% of patients, but only half of these patients exhibit
non-detectable levels of cancer cells 5 months after
treatment [15]. Even in those patients, small numbers
of chemotherapy-resistant cells can remain dormant in
the peritoneal cavity for several months before growing
exponentially [15]. However, as with many other types
of cancer, ovarian cancer is a prime candidate for macrophage-specific immunotherapy.
Tumor-associated macrophages (TAMs) are the most
abundant immune cell in most types of cancer, including epithelial ovarian cancer [16, 17]. TAMs are prevalent in both the solid tumor as well as the ascites fluid
associated with ovarian cancer progression. Ascites
development is correlated with severity of ovarian
cancer (present in over one-third of patients) and is
linked to poor disease prognosis as well as development of chemoresistance [18–20]. TAMs in both the
tumor and ascites promote an immunosuppressive
tumor microenvironment (TME), hinder the efficacy of
ICB, and drive tumor progression and metastasis [21,
22]. Several techniques to alter the TME, including
TAM ablation or limiting TAM recruitment, have been
attempted with moderate successes [23, 24]. However, a
potentially more robust method leverages macrophage
plasticity. This phenomenon provides the opportunity to target M2-like immunosuppressive TAMs and
“repolarize” them into an M1-like pro-inflammatory,
anti-tumor phenotype. Repolarizing TAMs for cancer
immunotherapy is a rapidly growing field of study with
encouraging early results [25, 26].
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Our lab has previously identified the nuclear factor-κB
pathway (NF-κB) as a target for repolarizing macrophages both in vitro and in vivo since this pathway
drives macrophage phenotype [27, 28]. This work provides evidence that modulating macrophage phenotype
in mouse cancer models induces beneficial therapeutic outcomes. Using transgenic mice, we have recently
demonstrated M1 macrophage repolarization, increased
cytotoxic T cell responses, and reduced tumor burden
in syngeneic mouse models of ovarian cancer [28]. The
goal of the present study is to evaluate a new translational approach involving a targeted nanoparticle-based
delivery of a siRNA cargo to specifically stimulate NF-κB
activity in ovarian TAMs.
Our group has extensive experience designing nanoparticle formulations for delivering siRNA to cells in vivo
[29–31]. We have previously used a small interfering RNA (siRNA) sequence specific for the inhibitor of
NF-κB alpha (IκBα). Because IκBα functions to inhibit
the canonical NF-κB pathway, our previous work confirmed that delivering siRNA against IκBα can increase
activity of the canonical pathway and induce M1 polarization [27, 29].
Although siRNA-based therapies are promising, delivery platforms are crucial to their success because oligonucleotides are unable to cross cell membranes and are
rapidly cleared from circulation when administered as
unformulated macromolecules [32]. Targeted formulations can enhance delivery of functional siRNA to the
appropriate cells while simultaneously minimizing activity in non-target cells and tissues [33, 34]. By combining
a siRNA against IκBα with a targeted delivery system,
we aim to increase the specificity of M1 activation to the
tumor microenvironment and limit off-target effects elsewhere. The phenotypic diversity of macrophages, often
characterized by the differing expression levels of various surface receptors, allows for targeting via the CD206
macrophage mannose receptor, which is overexpressed
on M2-polarized macrophages and TAMs [35]. The
overexpression of CD206 on immunosuppressive TAMs
allows for targeting with mannose-decorated delivery
systems [25, 27, 36]. Specifically, polymers designed to
form nanoscale micelles containing siRNA and decorated
with mannose enable the targeted delivery of RNA interference (RNAi) therapies that modulates macrophage
phenotype [27]. These micelles are spherical with diameters of 100-150 nm to promote clathrin-mediated endocytosis into the targeted macrophages, which has been
extensively documented [37–39]. Our group has previously demonstrated MnNP targeting to macrophages
using a mannosylated triblock copolymer [36, 40]. This
system has since been improved via the development of a
diblock copolymer that is more reproducible and simpler
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to fabricate [41]. The mannose-decorated diblock copolymer was shown to successfully target M2-polarized bone
marrow-derived macrophages (BMDMs) and repolarize
them to an M1 phenotype [27].
Mannosylated nanoparticle (MnNP) delivery systems
can be especially beneficial in the context of ovarian cancer. EOCs with high levels of immunosuppressive TAMs,
in both the solid tumor and ascites, result in poor prognosis for patients while cases with elevated M1-polarized
macrophages are correlated with increased overall survival and progression-free survival [42, 43]. Furthermore,
intraperitoneal (IP) injection of nanoparticles allows for
localized delivery with limited risk for off-target accumulation or rapid clearance that is often associated with
intravascular (IV) delivery [30]. The potential for targeted
repolarization of TAMs in EOC led to the hypothesis that
IP injection of MnNPs loaded with IκBα siRNA (IκBαMnNP) will locally target and reprogram macrophages to
induce anti-tumor immunity in mouse models of ovarian
cancer.
This study follows-up on our previous work by utilizing the optimized MnNPs to deliver IκBα siRNA to
TAMs in mouse models of ovarian cancer. Two models of
ovarian cancer were used to evaluate the effects of IκBαMnNPs on TAMs. The ID8 ovarian tumors on a C57Bl/6
background enabled examination of treating late-stage
disease while the TBR5 ovarian tumors on an FVB background allowed for evaluation of early-stage treatment
in an aggressive disease model. MnNP biodistribution
was evaluated to confirm limited off-target delivery in
both models. Tumor-bearing mice were treated with
IκBα siRNA-loaded MnNPs, scrambled siRNA-loaded
MnNPs, or PBS to evaluate changes in tumor burden in
terms of tumor weight and ascites accumulation. The
safety profile of the two treatment regimens was also
evaluated to characterize any toxicities caused by MnNP
administration. Immune cell composition, macrophage
phenotypes, and cytokine signaling were evaluated to
investigate the mechanisms leading to differential outcomes and, ultimately, to demonstrate the effects of TAM
repolarization on tumor suppression.

Materials and methods
Materials

All materials were purchased from Sigma-Aldrich
unless otherwise noted. Monomethyl ether hydroquinone inhibitors were removed from dimethylaminoethyl methacrylate (DMAEMA) and butyl methacrylate
(BMA) using an activated basic aluminum oxide column.
All DNA and RNA oligonucleotides were purchased
from Integrated DNA Technologies (Coralville, IA). For
in vivo biodistribution studies, double stranded DNA
(dsDNA) designed to be length-matched to therapeutic
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IκBα siRNA and conjugated with a cyanine-5 (Cy5) fluorophore was used. IκBα siRNA sequence was based on
previous studies and the scrambled siRNA sequence was
randomized from the IκBα sequence and analyzed via
the Basic Local Alignment Search Tool (BLAST, NCBI)
to ensure no off-target effects with our sequence [27, 29].
Oligonucleotide sequences are listed in Supplemental
Table 1.
Polymer synthesis

The mannose-poly (ethylene glycol)-(DMAEMA-coBMA) (MnPEGDB) polymer was fabricated as previously
described [27, 36, 40, 41]. Nucleophilic substitution of
propargyl bromide with D-mannose to form mannosealkyne was performed and characterized previously [27].
The core of the micelle comprises a diblock copolymer
fabricated using 4-cyano-4-(ethylsulfanylthiocarbonyl)sulfanylpentanoic acid (ECT) as a chain transfer agent
(CTA) conjugated to an azide-functionalized PEG (AzPEG). The Az-PEG-ECT was then RAFT polymerized
to DMAEMA and BMA as previously described to create a “smart” polymer capable of encapsulating anionic
siRNA and inducing endosomal escape upon uptake [27,
41, 44]. The AzPEGDB was then reacted with Mn-alkyne
(1:3 azide:alkyne molar ratio) via copper-catalyzed azidealkyne cycloaddition (CuAAC) using a previously optimized copper catalyst concentration of 0.75 mM with
5 mM of sodium ascorbate [27]. Chemical structures and
1
H-NMR for all reaction steps are shown in Supplemental Figs. S1-4, and mannose conjugation was verified with
Fourier transform infrared (FTIR) spectroscopy as previously described (Supplemental Fig. S5) [27]. All chemical
structures were made using ChemDraw (PerkinElmer).
FTIR spectroscopy was performed at the Vanderbilt
Institute of Nanoscale Science and Engineering (VINSE)
and all 1H-NMR experiments were performed at the Vanderbilt Small Molecule NMR Facility on a 400 MHz spectrometer (Bruker).
Nanoparticle preparation

Nanoscale polymeric complexes were fabricated as previously described [27, 30, 41]. To form mannosylated-nanoparticles (MnNPs) with oligonucleotides, MnPEGDB
was dissolved in 90% (v/v) 10 mM citrate buffer (pH = 4)
with 200-proof ethanol (EtOH). MnNPs were complexed
with either Cy5-dsDNA, IκBα siRNA, or scrambled
siRNA for 30 minutes to form micelles before adding 5×
volume 10 mM phosphate buffer (pH = 8) for a final solution pH of 7.4. The micelle N+/P− ratio, determined by
mole ratio of protonated amines on the DMAEMA polymer to the number of phosphates on the oligonucleotides, was chosen as 10:1 based on previous studies [27,
41]. Nanoparticle size and zeta potential were evaluated
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using a Malvern Zetasizer located at VINSE, and the
results are shown in Supplemental Fig. S6. All in vitro
treatments were conducted with a final concentration of
50 nM oligonucleotides and all in vivo treatments were
performed using a dose of 1 mg/kg (1 mg of oligonucleotide/kg of mouse weight). For in vivo NP preparation, the
pH = 7.4 solution was diluted in sterile phosphate buffered saline (PBS) without magnesium and calcium and
centrifuged in 5000 MWCO Amicon® Ultra-15 Centrifugal Filters (Millipore Sigma; UFC905024) at 2000×g for
30 minutes. The concentrated NPs were diluted in PBS
(−/−) and centrifuged again before adding PBS to get to
the appropriate volume for a 1 mg/kg concentration. The
final preparation was filtered through a 0.45 μm syringe
filter before being used for intraperitoneal injection.
Cell culture and tumor induction

Unless otherwise noted, all cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, low glucose,
pyruvate, Gibco; 11,885,084) supplemented with 10%
fetal bovine serum (FBS, certified, Gibco; 16,000,044)
and 1% penicillin/streptomycin (P/S) at 37 °C in a 5%
CO2 humidified atmosphere. Luciferized ID8 ovarian tumor cells and TBR5 genetically modified ovarian
tumor cells were used as previously described [45–48].
TBR5 cells were from Dr. Sandra Orsulic [49] and luciferized ID8 cells were from Dr. Balkwill [50]. All animal
work was reviewed and approved by the Vanderbilt University Institutional Animal Care and Use Committee
(IACUC). The ID8 cells were used in syngeneic C57Bl/6
background mice while TBR5 cells were used in syngeneic FVB background mice. For tumor induction, cells
were resuspended in sterile PBS at a concentration of
5 × 106 cells/200 μL. A sterile 3 mL Luer-Lok™ syringe
with an 18G needle was used to inject of 5 × 106 cells
tumor cells in 200 μL PBS intraperitoneally (IP) into each
mouse. At endpoint, all mice were euthanized via carbon
dioxide inhalation with secondary cervical dislocation as
approved by IACUC protocols.
Primary bone marrow-derived macrophages (BMDMs)
were isolated from healthy female wild-type FVB mice
and immortalized NGL-BMDMs were previously derived
from NF-κB green fluorescent protein (GFP)-luciferase
(NGL) reporter transgenic mice on an FVB background
[51–53]. BMDMs were used for background in vitro
assays and M2-polarized BMDMs are commonly used as
surrogates for TAMs as a practical substitute [27, 29, 54].
Culturing and treating bone marrow‑derived macrophages

Immortalized NGL-BMDMs were used from frozen
stocks for in vitro experiments [53]. NGL-BMDMs
were plated in 6-well plates at 1 × 106 cells/well in 2 mL
of DMEM (ThermoFisher; 11,995,073) supplemented
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with 10% FBS and 1% P/S. The macrophages were polarized to M1 with 10 ng/mL each of IFN-γ and LPS for
24 hours and to M2 with 10 ng/mL of IL-4 for 48 hours.
M2-polarized NGL-BMDMs were treated with ScrMnNPs or IκBα-MnNPs for 24 hours before collecting
cells for luminescent measurements. Samples were prepared for luminescence readings using a Luciferase Assay
System (Promega; E4030) following the manufacturer’s
instructions.
In vivo biodistribution studies in ovarian tumor‑bearing
mice

For the preliminary 24-hour delivery study, 6 female
C57Bl/6 mice were injected IP with 5 × 106 ID8 ovarian tumor cells in 200 μL PBS. Tumors developed for
8 weeks before treatment. Control mice were injected
with 200 μL PBS and treatment mice received 200 μL
PBS containing MnNPs loaded with Cy5-dsDNA at the
previously listed dosage. After 24 hours, the mice were
sacrificed and the ascites, tumors, and spleens were
collected. The ascites was centrifuged at 1500 rpm for
5 minutes, supernatant collected, and red blood cells
(RBCs) lysed with 5 mL Geyz lysing buffer (4.15 g NH4Cl,
0.5 g KHCO3 in 500 mL MilliQ water) for 5 minutes at
37 °C. This step was repeated as needed until a clear pellet was obtained. The resulting cells were resuspended in
PBS with 1% BSA and snap-frozen in liquid nitrogen for
RNA isolation or protein analysis. The solid tumors were
collected into 3 mL DMEM (MT-10-13-CV) containing
10% FBS and 1% P/S for 1 hour on ice. The tissue was cut
into small pieces and resuspended in 3 mL DMEM with
200 μL Collagenase A (Roche; 10,103,578,001), 300 μL
hyaluronidase (Sigma; H4272), 500 μL DNase I (Sigma;
D5025), and 30 μL amphotericin B (ThermoFisher;
15,290,026) and placed at 37 °C for 2 hours with frequent vortexing. The solution was filtered through a
70 μm strainer to form a single cell suspension used
for flow cytometry. Tumors were then treated with the
same RBC lysis buffer as the ascites. Similarly, spleens
were collected in DMEM (10% FBS, 1% P/S) for 1 hour
on ice, chopped into small pieces, and immediately filtered through a 70 μm strainer twice. The final single cell
suspension was treated with RBC lysis buffer before flow
analysis.
The long-term biodistribution study was performed
in the TBR5 ovarian tumor model. 10 female FVB mice
received IP injections of 5 × 106 TBR5 cells in 200 μL
PBS (day 0). Tumors developed for 7 days before starting treatment on day 7. Mice either received IP injections
of 100 μL PBS or 100 μL Cy5-MnNPs. Treatments were
performed on days 7, 10, 14, and 17 before takedown on
day 18. Single cell suspensions were made from tumors,
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ascites, and spleen as previously described and used for
flow cytometry analysis.
Flow Cytometry of in vivo biodistribution

Single cell suspensions were obtained from the tumors,
ascites fluid, and spleens of either ID8 or TBR5 tumorbearing mice. For ID8 24-hour biodistribution, the
cells were resuspended in flow buffer (PBS with 2 mM
EDTA and 0.5% (v/v) BSA) at 1 × 106 cells/50 μL buffer.
The following anti-mouse antibodies were used: CD45
PE-Cy7 (eBioscience; 25-0451-82), F4/80 PE (eBioscience; 12-4801-82), and Gr-1 Alexa Fluor 700 (eBioscience; 53-5931-82). After staining for 30 minutes, the cells
were rinsed in PBS and resuspended in flow buffer before
running flow analysis at the Vanderbilt Flow Cytometry
Shared Resource. All flow analysis was performed using
FlowJo v10.7.1. Flow gating strategy is shown in Supplemental Fig. S7.
For the TBR5 biodistribution study, flow cytometry
was performed as previously described [55]. The cells
were incubated in an Fc block (BD Biosciences; 553,142)
for 10 minutes at RT, stained for surface markers for
15 minutes at RT, washed with a FACS buffer containing PBS with 2% (v/v) FBS, and resuspended in the FACS
buffer for flow analysis on a Miltenyi MACSQuant Analyzer 10 or 16. The eBioscience™ Foxp3/transcription
factor staining buffer kit (Fisher Scientific; 00-5523-00)
was used for intracellular staining. After surface staining, the cells were fixed and permeabilized for 20 minutes at 4 °C before staining for intracellular markers for
30 minutes at 4 °C. To quantify cell viability, a Ghost Dye
Red 780 viability marker (1:4000, Cell Signaling Technology; 18452S) was used. The following anti-mouse
antibodies were used: CD45 BV510 (1:1600, BioLegend;
103,138), CD3 FITC (1:200, BioLegend; 100,204), CD4
PerCP-Cy5.5 (1:600, BioLegend; 100,540), CD8a PE
(1:800, eBioscience; 12-0081-82), B220 e450 (1:400, ThermoFisher; 48-0452-82), NKp46 PE-Cy7 (1:200, BioLegend; 137,618), CD11c PE (1:1000, BioLegend; 117,308),
CD11b e450 (1:1600, ThermoFisher; 48-0112-82), F4/80
PE-Cy7 (1:800, BioLegend; 123,114), Ly6C FITC (1:4000,
BioLegend; 128,006), and Ly6G PerCP-Cy5.5 (1:800, BioLegend 127,616). Flow cytometry data were analyzed
with FlowJo v10.7.1. Representative gating strategies of
ascites, tumors, and spleens are shown in Supplemental
Figs. S8-10.
In vivo tumor studies

Treatment of the ID8 ovarian tumor model was formulated as a late-stage disease treatment. Similar to uptake
studies, 5 × 106 ID8 ovarian tumor cells in 200 μL PBS
were IP injected into 15 female C57Bl/6 mice (day 0)
and allowed to develop tumors for 7 weeks. Starting on
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day 49, mice received IP injections of 100 μL PBS, ScrMnNPs, or IκBα-MnNPs for 3 consecutive days. MnNPs
were given at a dose of 1 mg/kg. The mice were euthanized 1 day after the final treatment. Blood samples were
collected for liver (aspartate aminotransferase, AST, and
alanine aminotransferase, ALT) and kidney (blood urea
nitrogen, BUN) enzyme measurements and the ascites
volume was measured and collected. Normal ranges
for serum AST, ALT, and BUN levels were referenced
from the Vanderbilt University Translational Pathology Shared Resource (TPSR). Tumors and spleens were
then harvested. The ascites fluid was collected, centrifuged, and the supernatant stored for protein serum concentration analysis as described above. The remaining
ascites cell pellet was further processed with RBC lysis
as described above until the cell pellet was clear. The cell
pellet was frozen at − 80 °C for RNA isolation. Tumors
were weighed, cut in half, and one half was snap frozen
in liquid nitrogen for RNA isolation. The other tumor
half and the entire spleens were fixed in 10% formalin for
48-72 hours for histology before being switched to 70%
EtOH. Processing, embedding and sectioning, and hematoxylin and eosin (H&E) staining of tumor tissue, as well
as blood chemistry analyses, were performed by the Vanderbilt University Medical Center (VUMC) Translational
Pathology Shared Resource (TPSR) core. H&E-stained
tissues were imaged using the EVOS XL Core microscope
(ThermoFisher) on 4x and 10x brightfield magnification.
The faster developing TBR5 model was used to model
a more aggressive, early-stage treatment strategy. 5 × 106
TBR5 ovarian tumor cells in 200 μL PBS were IP injected
into 15 female FVB mice (day 0) and allowed to develop
tumors for 7 days. A biweekly treatment was adopted to
combat the aggressive growth. Mice received IP injections of 100 μL PBS, Scr-MnNPs, or IκBα-MnNPs on days
7, 10, 14, 17, and 21 and the mice were sacrificed on day
22. For the extended study, additional MnNP treatments
were administered on days 24 and 28 before euthanizing
mice on day 29. Similar to the ID8 model, blood samples
and ascites were collected immediately after takedown
before surgically removing the spleens and tumors. The
ascites was centrifuged and supernatant collected. The
tumors were weighed and then split into two samples:
one for fixation and one for snap freezing for RNA isolation. Spleens were fixed as previously described. The
same analyses performed on the ID8 ovarian tumors
were repeated here. For flow cytometry analysis, CD3
APC (1:200, BioLegend; 100,236) and CD8a AF488
(1:1600, BioLegend; 100,723) were used in place of CD3
FITC and CD8a PE used for biodistribution. The rest of
the panel was the same with the addition of the following
anti-mouse antibodies: CD206 APC (1:500, BioLegend;
141,708), FOXP3 PE (1:125, ThermoFisher; 12-5773-82),
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and PD-1 PE (1:100, BioLegend; 135,206). Flow gating
strategy was repeated as previously shown. To visualize tumor cells populations, cells were gated on forward
scatter (FSC) vs side scatter (SSC), single cells (FSCarea vs FSC-height), live/dead, and CD45-. The CD45cells were visualized again as FSC vs SSC where a clear
population of “big” SSC-high (SSChi) cells were present
only in cells from the solid tumors and ascites, but not
the spleen. Representative tumor cells gating is shown in
Supplemental Fig. S11.
Immunofluorescent staining for confocal imaging of tumor
sections

The protocol of immunofluorescent staining and analysis has been previously described [28]. To evaluate CD8
T cell infiltration, the primary antibody rat anti-mouse
CD8 (Novus Biologicals; BP1-49045SS, 1:100) was used
with a secondary goat anti-rat IgG Alexa Fluor 488
(Abcam; ab150157). Previously sectioned tumor samples were deparaffinized in Xylenes 2x for 10 minutes
each. The samples were then rehydrated in 100% EtOH
2x for 2 minutes each, and then once each in 90, 80, and
70% EtOH (v/v in DI water) for 2 minutes. The slides were
then incubated on a shaker in 0.1% Sudan Black Dye
solution (diluted in 70% EtOH) for 20 minutes before one
more 2-minute wash in 50% EtOH. The sections were
then permeabilized in 1X Tris-buffered saline (TBS) with
0.1% Tween 20 (TBST) for 20 minutes, rinsed in TBS
for 5 minutes, and finally rinsed briefly with Milli-Q DI
water. Antigen retrieval was performed by placing slides
in a rice cooker with a 10 mM sodium citrate solution
(pH = 6.0) with 0.1% Tween 20 and heated for 15-20 minutes before cooling at RT for 30 minutes. The slides were
then washed 3x with TBS for 5 minutes each. Slides
were treated with a blocking buffer comprised of 4 mL
0.5% TBST, 0.04 g bovine serum albumin, and 250 μL
goat serum (Abcam; ab7481) for 1 hour in a humidified
chamber at RT. The blocking buffer was aspirated and
100 μL of primary antibody was added and incubated at
4 °C overnight. The primary antibody was aspirated and
each slide washed 3x for 10 minutes each in TBST and
then rinsed a final time with TBS for 5 minutes while
shaking. The TBS was aspirated and 100 μL of secondary antibody was diluted in blocking buffer (1:1000) and
incubated at RT in the dark for 2 hours. The slides were
washed 3x for 10 minutes each in TBST followed by a single 5-minute wash in TBS on a shaker. DAPI (0.1 μ/mL)
was added to each slide and incubated at RT for 5 minutes to stain cell nuclei. The slides were washed 2x for
3 minutes each in TBS and then 20 μL ProLong™ Gold
Antifade Mountant (ThermoFisher; P36930) was added
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to preserve fluorescent signal. Slides were stored at 4 °C
until imaging was performed via fluorescent microscopy
(Nikon C1si + confocal microscope system on Nikon
Eclipse Ti-0E inverted microscope base, Plan APO VC
20× objective, 405/488 dichroic mirror). Images were
analyzed using Fiji in ImageJ [56].
RNA extraction for quantitative reverse transcription
polymerase chain reaction (qRT‑PCR)

For in vitro BMDM experiments, RNA was isolated using
the RNeasy Mini Kit (Qiagen; 74,106) and residual DNA
was removed using the RNase-Free DNase set (Qiagen;
79,256). cDNA was synthesized with SuperScript IV
reverse transcriptase kit (Invitrogen; 18,090,050). Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad; 1,725,270) on a
CFX96 real-time PCR instrument and software (Bio-Rad)
through the VUMC Molecular Cell Biology Resource
(MCBR) core.
For in vivo experiments, RNA was extracted from both
the ascites cells and tumor cells using TRIzol™ (Invitrogen; 15,596,026) and a Direct-zol RNA Miniprep kit
(Zymo Research; R2050). Snap frozen tumor samples
were ground into small pieces with a mortar and pestle
before suspending in 300 μL TRIzol solution. The ascites
pellet was resuspended in 300 μL TRIzol solution. Both
solutions were used with the Direct-zol RNA Miniprep
kit following the manufacturer’s instructions. Final RNA
concentration was measured with a NanoDrop 200 spectrophotometer (Biotek). cDNA fabrication and qRTPCR were performed as described above. All primer
sequences are listed in Supplemental Table 2. For all
experiments, target genes were normalized to a housekeeping gene (B2M or GAPDH) to obtain the ΔCT value.
All qRT-PCR data is shown as relative expression using
the 2-ΔΔCT method.
Western blot

Protein isolated from ascites cells in the TBR5 experimental model was used for western blot analysis of
IκBα expression. Whole protein isolation, western blotting, and signal detection were performed as previously
described [57]. Primary antibodies used were rabbit
polyclonal anti-IκBα (1:100 dilution, Cell Signaling
Technology; 9242). Equal loading was confirmed using
mouse monoclonal anti-histone H3 (1:1000 dilution,
Cell Signaling Technology; 14269S) as a loading control.
To image loading control and experimental antibody
on the same blot, the gel was cut prior to hybridization.
The pieces of the uncropped blot are shown in Supplemental Fig. S12.
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Statistical analysis

All statistical analyses were performed using a one-way
ANOVA with Tukey’s multiple comparison test in the
case of two or more groups, a two-way ANOVA with
Tukey’s multiple comparison test in the case of two or
more groups in two or more sets, or a two-tailed student’s
t-test in the case of only two groups, all with α = 0.05.
Statistical analyses were performed using GraphPad
Prism v8.4.3. All figures were made using Adobe Photoshop 2020 v21.2.2.

Results
Quantifying changes in NF‑κB activation in MnNP‑treated
macrophages

Knockdown of IκBα by targeted siRNA results in activation of the canonical NF-κB pathway known to promote inflammation through the M1 polarization of
macrophages [58, 59]. To assess activation of canonical NF-κB following treatment with IκBα siRNA loaded
into MnNPs, immortalized BMDMs derived from
NF-κB green fluorescent protein (GFP)-luciferase (NGL)
reporter transgenic mice (FVB background) were cultured [29, 51]. The NGL-BMDMs express a GFP-luciferase fusion protein in response to NF-κB activation
allowing for luminescence as a method to evaluate effects
of treatment in the context of differently polarized macrophages. BMDMs were polarized to an M2 phenotype
via interleukin-4 (IL-4) stimulation for 24 or 48 hours
before treating with MnNPs for 24 hours. Control
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groups of M1-polarized or unpolarized (M0) BMDMs
were also included. M1 polarization was induced via
treatment with interferon-γ (IFN-γ) and lipopolysaccharide (LPS) for 24 hours. For the 48 hour-stimulated
M2 BMDMs, the IκBα-MnNP treatment significantly
increased luminescence compared to both the PBS control and the Scr-MnNP treatment, indicating activation
of canonical NF-κB (Fig. 1). M2 macrophages treated
with MnNPs loaded with IκBα siRNA activated NF-κB to
levels equivalent to M1 macrophages treated with PBS as
estimated by luminescence intensity, indicating a robust
shift in macrophage phenotype induced by IκBα-MnNP
treatment. Interestingly, for the 24 hour-stimulated M2
BMDMs, both Scr-MnNP and IκBα-MnNP treatments
increased luminescence, indicating potential activation
of canonical NF-κB due to the mannosylated carriers
themselves. There was no significant change in luminescent intensity for Scr-MnNP treatments between 24- and
48-hour IL-4 stimulation, while the IκBα-MnNP treatment significantly increased luminescent intensity for the
longer stimulated M2 macrophages.
Biodistribution analysis of MnNPs in a late‑stage ID8
ovarian tumor model

Biodistribution studies were conducted to evaluate
in vivo delivery of MnNPs to specific cell populations.
Female C57Bl/6 mice received intraperitoneal (IP)
injections of 5 × 106 ID8 ovarian tumor cells and were
monitored for tumor development for 8 weeks. The ID8

Fig. 1 NF-κB Activation in MnNP-Treated Polarized NGL-BMDMs. BMDMs isolated from NGL reporter mice were polarized to M1 (IFN-γ + LPS) or
M2 (IL-4, 24 or 48 hours) or left unpolarized (M0) and examined for luminescent readout. The M2-polarized BMDMs were also treated with MnNPs
for 24 hours before measuring luminescence. For the 24 hour-polarized M2 BMDMs, the Scr- and IκBα-MnNP treatments both increased NF-κB
activation, but this effect was more pronounced in the 48-hour IL-4-treated BMDMs, especially with the IκBα-MnNP (n = 3, *p < 0.05 **p < 0.001
##p < 0.001)
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model is slow-developing (> 7 weeks) and is often used
for studying late-stage ovarian cancer [47, 60, 61]. These
mice received a single IP injection of MnNPs loaded
with Cy5-labeled double-stranded DNA (Cy5-MnNPs)
8 weeks after tumor induction. The ascites fluid, tumors,
and spleens were collected from the mice 24 hours after
MnNP administration and processed for flow cytometry.
Cy5 fluorescence was used to estimate MnNP biodistribution. The general cell population was gated on forward-scatter (FSC) vs. side-scatter (SSC). Immune cells
were gated on CD45 followed by F4/80 vs. Gr-1 to visualize immune cell subsets. The MnNPs were located almost
exclusively in the tumor and ascites with 15.4% of cells in
the tumor and 59.7% of cells in the ascites gating positive
for Cy5 compared to < 1% of cells in the spleens (Fig. 2A).
Additional gating on the general macrophage population (CD45+/F4/80+) revealed that 75.7% of TAMs and
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61.3% of the macrophages in the ascites were associated
with Cy5-MnNPs, consistent with the anticipated delivery of cargo to these cell types in the peritoneal cavity
(Fig. 2B). Gr-1 gating demonstrated the same trends in
both mature macrophage (F4/80+/Gr-1-) and myeloid
cell (F4/80−/Gr-1+) populations, with high percent
uptake in the tumor and ascites and negligible delivery to
the spleen (Fig. 2C, D). These results suggest that even a
single IP injection of MnNPs examined after 24 hours is
able to deliver the payload to high percentages of macrophages in the tumors and ascites.
Endpoint MnNP treatment of late‑stage disease reveals
encouraging effects

To evaluate the anti-tumor efficacy of MnNP treatments in late-stage disease, ID8 ovarian tumor cells were

Fig. 2 MnNP Biodistribution in ID8 Tumor Model. C57Bl/6 mice bearing ID8 ovarian tumors were treated IP with Cy5-MnNPs. After 24 hours,
the ascites, tumors, and spleens were collected for flow cytometry analysis. A The general cell population gated on FSC vs. SSC revealed a high
percentage of MnNP+ cells in the ascites and almost 20% of cells in the tumor, but negligible delivery to any cells in the spleen. B Gating on
CD45+/F4/80+ macrophages revealed that about 60% of macrophages in the ascites and ~ 75% of TAMs were MnNP+. Additional gating for (C)
Gr-1- mature macrophages and (D) Gr-1+ myeloid cells also revealed high percentages of MnNP uptake in the ascites and tumor (n = 3, *p < 0.05
**p < 0.001)
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injected into the peritoneal cavity of female C57Bl/6
mice and allowed to progress for 7 weeks. Once these
mice approached humane endpoint, MnNP treatments
were administered by IP injection daily for 3 consecutive days. The treatment groups included a PBS control
or MnNPs containing the Scr siRNA (Scr-MnNPs) or
the IκBα siRNA (IκBα-MnNPs). Mice were euthanized
24 hours after the final injection (Fig. 3A). This model
was chosen because ID8 ovarian tumors are known to
produce high ascites volumes, which comprise large
populations of immunosuppressive macrophages, and
reflect a significant subpopulation of human ovarian
cancers [48]. In this way, the ID8 model could be used
to evaluate the effects of MnNP-mediated siRNA delivery to immunosuppressive macrophage populations
in hopes of seeing changes in the immune cells. Additionally, a 3-consecutive day treatment at endpoint was
used to evaluate toxicity of multi-day MnNP injections.
Importantly, limited toxicity was observed in mice
treated with MnNPs with serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT),
and blood urea nitrogen (BUN) all falling within normal ranges (indicated as horizontal dotted lines) despite
slight elevation in AST levels in the IκBα-MnNP treatment (Fig. 3B-D). While the 3-day MnNP treatment

Page 9 of 19

did not result in toxicity, there was also no significant
change in tumor burden as evaluated by ascites volume
and tumor weight at endpoint (Fig. 3E, F). The trend
of decreasing ascites volume from 5.1 ± 1.4 mL in the
control to 2.8 ± 1.1 mL in the IκBα-MnNP treatment
provided encouragement that beneficial changes were
occurring, but this effect was minimal due to the latestage treatment of advanced disease. However, hematoxylin and eosin (H&E) staining of tumor sections revealed
visible differences in the treatment groups, most noticeably areas of decreased epithelial cellularity that could
result from an increase in cell death (Supplemental Fig.
S13). For cells collected from the ascites, there was a significant increase in RNA expression of the M1 marker
C-C motif chemokine ligand 3 (CCL3) and a trend of
increased tumor necrosis factor-α (TNF-α) expression in
the IκBα-MnNP treatment compared to control (Fig. 3G,
H). Finally, there was a significant decrease in immunosuppressive interleukin-6 (IL-6) expression in both
MnNP treatments (Fig. 3I). Expression of an additional
M1 marker C-X-C motif ligand 9 (CXCL9), a chemokine
responsible for attracting CD8 T cells, trended upward
in the ascites, while CCL3 and TNF-α expression in cells
from solid tumors also trended upward but not significantly (Supplemental Fig. S14).

Fig. 3 Endpoint Analysis of ID8 Tumors Treated with Therapeutic MnNPs. A Treatment schematic for development of ID8 ovarian tumor model
and 3-day MnNP treatment. Serum levels of (B) AST, (C) ALT, and (D) BUN were evaluated at endpoint. AST and ALT were significantly elevated
in IκBα-MnNP treatment, but still within normal ranges while BUN levels were unchanged (n = 5, *p < 0.05). Changes in (E) ascites volume and
(F) tumor weight at takedown (n = 10, color indicates experimental groupings). RNA isolated from the ascites cells revealed increases in the
inflammatory cytokines (G) CCL3 and (H) TNF-α (PBS control n = 5, Scr-MnNP n = 3, IκBα-MnNP n = 4, *p < 0.05). I Cells in the ascites also significantly
decreased in expression of IL-6 in both MnNP treatments (PBS control and IκBα-MnNP n = 4, Scr-MnNP n = 5, *p < 0.05)

Glass et al. BMC Cancer

(2022) 22:497

Biweekly treatment of ovarian tumors reveals
macrophage‑specific delivery in ascites and solid tumors

To evaluate the effects of repetitive IκBα-MnNP treatment on a more aggressive tumor model, the TBR5 ovarian model in FVB mice was adopted. Biodistribution
was assessed to confirm preferential in vivo delivery of
MnNPs to macrophage populations in the ascites and
solid tumor. The TBR5 model exhibits rapid disease progression (over the course of 28 days) and provides a platform to characterize the impact of a feasible treatment
schedule in an aggressive model. Due to rapid progression, a biweekly (twice per week) treatment regimen for
2 weeks (total of 4 treatments) was used. Cy5-MnNPs
were delivered via IP injection to evaluate biodistribution. One day after the final treatment, the ascites, solid
tumors, and spleens were collected and processed for
flow cytometry analysis. Initial gating on the immune cell
population (CD45) revealed that 89% of CD45+ immune
cells in the ascites and 34.1% of CD45+ immune cells in
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the solid tumor were positive for Cy5-MnNPs compared
to 11.4 and 2.6% uptake in the non-immune cell (CD45-)
populations of the ascites and tumors, respectively
(Fig. 4A). Additionally, there was negligible uptake (< 1%)
in any cells in the spleen, supporting our hypothesis that
IP delivery can abrogate the off-target delivery normally
associated with IV treatment.
Additional gating on specific immune cell populations was performed to examine macrophage targeting. Lymphocyte gating included CD45+/CD3+/CD4+
and CD45+/CD3+/CD8a + markers for CD4 and CD8
T cells, respectively. B cells were gated CD45+/CD3−/
B220+ and natural killer (NK) cells were gated CD45+/
CD3−/NKp46+. Myeloid populations were gated
CD45+/CD11c+/CD11b- for dendritic cells (DCs) and
CD45+/CD11c−/CD11b + for macrophages (F4/80hi)
and monocytes (F4/80lo). Macrophages and monocytes
were further gated Ly6C+/Ly6G- to remove neutrophils
and eosinophils [62]. When examining delivery to the

Fig. 4 Biodistribution of Biweekly MnNP Treatment in TBR5 Model. MnNP biodistribution in the TBR5 ovarian tumor model was examined via flow
cytometry. A Cy5-MnNPs demonstrated significant increase in uptake in CD45+ immune cells in both the ascites and solid tumor compared to the
CD45- populations (n = 5, ##p < 0.001). MnNPs were also associated with over 89% of CD45+ cells in the ascites and 30% of CD45+ cells in the solid
tumor (**p < 0.001). B Direct comparison of the different organs for macrophages, monocytes, and other immune cells revealed targeted delivery to
the tumors and ascites with minimal off-target delivery to the spleens (n = 5, **p < 0.001). Macrophages displayed significantly elevated %MnNP+
levels compared to most other immune cells in the (C) tumor, (D) ascites, and (E) spleen. The %MnNP+ macrophage population was significantly
higher than all other immune cell subtypes in the tumor, and higher than all other subtypes except monocytes in the ascites and spleen (n = 5,
*p < 0.05, **p < 0.001)
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macrophage (CD11b+/F4/80hi), monocyte (CD11b+/
F4/80lo), and other immune cell (CD11b−/F4/80-) populations in the different organs, the Cy5-MnNPs were
almost exclusively localized to the macrophages and
monocytes in the ascites and tumors with negligible
uptake in the spleen (Fig. 4B). In tumors, MnNP delivery was significantly greater in macrophages compared
to all other immune cell populations (Fig. 4C). Additionally, 85.7% of macrophages and 84.3% of monocytes in
the ascites were Cy5-MnNP+, which was significantly
elevated compared to all other immune cell populations
(Fig. 4D). Finally, only 3.9% of macrophages in the spleen
exhibited uptake of Cy5-MnNPs, demonstrating limited
off-target delivery (Fig. 4E). These results demonstrate
the intended targeting to TAMs as well as macrophages
in the ascites with minimal off-target delivery to other
immune cells or organs. Additionally, the biweekly treatment adopted for the aggressive tumor model exhibited

Page 11 of 19

greater MnNP uptake than observed in the previously
used late-stage ID8 model.
Delivery of IκBα‑MnNPs to TAMs prevents ascites
accumulation and alters immune cell phenotype

The TBR5 ovarian tumor model was used to elucidate the
effects of IκBα-MnNP treatment on an aggressive ovarian
tumor model. After tumor cell injection on day 0, MnNPs
were injected on days 7, 10, 14, 17, and 21 before mice
were humanely sacrificed on day 22 (Fig. 5A). Serum was
collected and evaluated for AST, ALT, and BUN levels as
previously described and, similar to the ID8 model, there
was no detectable toxicity as a result of MnNP treatment (Fig. 5B-D). In contrast to the ID8 model, MnNP
treatment in the TBR5 model significantly decreases
ascites accumulation and slightly decreases tumor burden (Fig. 5E, F). Additionally, the weight gain associated
with ascites fluid buildup in the PBS control group was

Fig. 5 Endpoint Analysis of Biweekly MnNP Treatment in TBR5 Model. A Treatment schematic for development of TBR5 ovarian tumor model and
biweekly MnNP treatment. Serum was collected at endpoint to evaluate circulating levels of (B) AST, (C) ALT, and (D) BUN (n = 5). Changes in (E)
ascites volume and (F) tumor weight at endpoint (n = 15, *p < 0.05). G Western blot analysis of cells in the ascites revealed changes in IκBα protein
levels (cropped image of western bands). RNA was collected from ascites cells and examined for expression of (H) CXCL9, (I) IL-6, and (J) Arginase-1
(PBS Control n = 4, Scr- and IκBα-MnNP n = 3, *p < 0.05, **p < 0.001). RNA collected from tumor cells was examined for expression of (K) TNF-α and
(L) Arginase-1 (n = 5, *p < 0.05, **p < 0.001)
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abrogated in the MnNP-treated mice (Supplemental Fig.
S15).
Similar to the ID8 model, there were clear indications
of changes in tumor tissue as evaluated by H&E staining of tumor sections. The PBS control tumor appeared
to only contain healthy cells while the Scr-MnNP treatment revealed some indications of depleted tumor cell
populations based on observations in decreased cellularity (Supplemental Fig. S16). Meanwhile, the IκBα-MnNP
treatment appeared to result in immune cell infiltration
as evidenced by the increase in darker stained areas in
the tumor sections (Supplemental Fig. S16). In both the
ascites and tumor cells, there was a trend of decreasing
IκBα RNA expression in mice treated with IκBα-MnNPs,
but this change was not significant (Supplemental Fig.
S17). Worthy of note was the observation of a relative
increase in IκBα expression between the PBS control and
the Scr-MnNP treatment in the ascites, which was abrogated by IκBα-MnNP treatment. However, there was a
clear decrease in IκBα protein levels in the cells isolated
from the ascites, indicating functionality of the IκBα
siRNA in vivo (Fig. 5G). Delivery of IκBα-MnNPs also
significantly increased expression of CXCL9 (M1 marker)
and decreased Arginase-1 expression (M2 marker), while
both MnNP treatments significantly decreased IL-6
expression (Fig. 5H-J). Importantly, MnNP treatment in
TBR5 mice also significantly increased expression of the
inflammatory cytokine TNF-α in the tumor, indicating
a shift in the tumor microenvironment (Fig. 5K). Finally,
there was a 5.2-fold decrease in Arginase-1 expression in
the IκBα-MnNP treatment compared to control (Fig. 5L).
Immunofluorescent (IF) staining of tumor sections for
CD8 T cells was used to visualize T cell infiltration into
treated tumors, which suggested an increase in CD8 T
cells in tumors treated with IκBα-MnNPs (Supplemental
Fig. S18).
Extended IκBα‑MnNP treatment alters immune cell
populations and provides robust anti‑tumor immune
response

An extended MnNP treatment in the TBR5 model was
used to further evaluate treatment effects on tumor progression and immune cell composition. TBR5 cells were
injected IP and treatments started on day 7 and administered twice per week for 7 total treatments (Fig. 6A).
The extended treatment significantly reduced both
ascites volume accumulation and final tumor weight
in both MnNP treatments, with a slightly more pronounced effect in the IκBα-MnNP treatment (Fig. 6B,
C). The weight gain associated with ascites development
was again abrogated similar to the previous study (Supplemental Fig. S19). Flow cytometry analysis was conducted to evaluate changes in immune cell populations
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after treatment. The percent of tumor cells (gated
CD45−/SSChi) in the ascites and tumor was significantly
decreased in the IκBα-MnNP treatment compared to the
PBS control (Fig. 6D, E). Similar to previous results, the
Scr-MnNP treatment led to a non-significant decrease
in the percent of tumor cells compared to the control,
indicating a slight therapeutic effect of the MnNPs themselves. Furthermore, the immune cells in the tumor and
ascites were altered due to MnNP treatments. The percent of M2-like TAMs (F4/80int/CD206+) was significantly decreased by IκBα-MnNP treatment in both the
tumor and ascites compared to both the PBS control and
Scr-MnNP treatment (Fig. 6F). The Scr-MnNP treatment
significantly decreased the percent of M2-like TAMs
compared to the control, but not to the level of IκBαMnNPs. Similarly, the ratio of M2/M1-like TAMs was
significantly decreased in both MnNP treatments, with
the effect being more pronounced in the IκBα-MnNP
treatment (Fig. 6G). Additional analyses revealed that
IκBα-MnNP treatment significantly increased the percent of classical (M1-like) monocytes (F4/80int/Ly6C+/
Ly6G-) in the ascites and significantly increased the percent of NK cells (CD3−/B220−/NKp46+) in the tumor
(Fig. 6H, I). Quantification of all immune cell populations also revealed trends of increasing CD8 T cells
and dendritic cells while the percent of CD4 T cells was
decreased (Supplemental Fig. S20). Taken together these
results demonstrate the robust anti-tumor effects of
IκBα-MnNP treatment due to altering the tumor immune
microenvironment.

Discussion
Repolarizing TAMs for cancer immunotherapy is a rapidly growing field of study with encouraging early results
[25, 26]. Our group has previously identified RNA interference (RNAi) as an ideal candidate for altering TAM
phenotype [29]. We have also demonstrated the antitumor effects of repolarizing TAMs by activating canonical NF-κB specifically in macrophages [28]. One of the
primary challenges associated with translating this successful approach to intact living systems is the need for
strongly preferential delivery of the siRNA payload to
TAMs in vivo. Our group has made tremendous progress
in developing a polymeric nanoparticle system capable of
targeting M2-like TAMs while simplifying and optimizing the fabrication process [27, 36, 40]. Additionally, our
combined expertise in studying ovarian tumors along
with the potential benefits of relatively localized delivery
via IP injections led to our decision to evaluate MnNP
treatment in models of ovarian cancer [48]. Additionally, Zhang, et al., recently demonstrated ovarian tumor
regression following IP administration of a different polymeric nanoparticle system loaded with mRNA encoding
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Fig. 6 Increased Therapeutic Benefit in Extended MnNP Treatment Model. A Treatment schematic for extended MnNP treatment in the TBR5 tumor
model. Changes in (B) ascites volume and (C) tumor weight at endpoint (n = 4, *p < 0.05, **p < 0.001). Flow cytometry gating on CD45−/SSChi cells
revealed significant changes in the percent of tumor cells in the (D) ascites and (E) tumors. Cells gated on F4/80int/CD206+ revealed significant
decreases in (F) the percent of M2-like TAMs and (G) the ratio of M2 (CD206+):M1 (CD206-) TAMs. The cells also revealed significant increases in (H)
classical monocytes (F4/80int/Ly6C+/Ly6G-) in the ascites and (I) NK cells (CD3−/B220−/NKp46+) in the tumor (n = 4, *p < 0.05, **p < 0.001)

interferon regulatory factor 5 (IRF-5) to TAMs. However,
this delivery system produced significant off-target IRF-5
activation in the spleens, causing M1 macrophage activation outside the TME [25]. In this study, we demonstrate
the advantages of treating ovarian tumor-bearing mice
with siRNA-loaded MnNPs to evaluate in vivo targeting
to TAMs, changes in immune cell composition, and subsequent effects on tumor progression.
The initial in vitro study was designed to evaluate the
ability of IκBα siRNA to activate the canonical NF-κB
pathway in M2-polarized BMDMs. We had previously
shown the knockdown of IκBα RNA expression and protein levels in M2 BMDMs treated with IκBα-MnNPs [27].
This study demonstrated that the knockdown of IκBα
in BMDMs also corresponded with increased canonical
NF-κB activation as evaluated by luminescent readout.
This study was also the first to reveal the potential for
the mannosylated carrier to stimulate pro-inflammatory

effects in macrophages even with an inert siRNA payload.
While the IκBα-MnNP increased luminescent readout to
the level of the M1 control BMDMs, the Scr-MnNP also
had an intermediate effect in increasing NF-κB activation. This result is consistent with other reports of inert
particles decorated with mannose modulating macrophage phenotype and promoting inflammation with
modest anti-tumor effects [25, 63]. Jaynes, et al., have
recently shown that even specific binding to the CD206
mannose receptor alters the receptor conformation and
leads to subsequent changes in macrophage phenotype
[64]. This phenomenon can provide extra benefit for our
purposes as we consistently observed a synergistic effect
of the MnNP loaded with IκBα siRNA producing a robust
repolarization of macrophages to a pro-inflammatory
phenotype.
After establishing NF-κB activation in vitro, the MnNPs
were used to treat two separate models of ovarian cancer.
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These models were chosen to evaluate two forms of treatment: late-stage treatment of advanced disease (ID8) and
early-stage, repetitive treatment of an aggressive disease model (TBR5). To examine biodistribution in the
late-stage model, the mice developed tumors until close
to humane endpoint (based on swelling due to ascites
buildup) and then a single MnNP dose was administered 24 hours before collection. These results revealed
that even 24 hours after a single treatment, MnNPs preferably associated with macrophages in the ascites and
tumor with no targeting to the spleen. This experiment
confirmed our hypothesis that an IP injection for treating ovarian tumors could nullify the concerns often associated with IV injection of nanoparticles. Furthermore,
the addition of the mannose moiety on the NPs prevented any off-target delivery to the spleen observed by
other groups using decorated NP systems [25]. By injecting directly into the peritoneal cavity, the MnNPs were
immediately exposed to the desired cell population in the
target organ where they deliver a payload with improved
specificity mediated via active endocytosis due to mannose conjugation. One of the major drawbacks with IV
delivery of nanoparticles is the reliance on the enhanced
permeability and retention (EPR) effect. While the EPR
effect has been a cornerstone of developing nanomaterials therapies to target solid tumors, recent evidence
shows the many challenges still hinder tumor targeting
[65–67]. Furthermore, to ensure a therapeutic dose actually reaches the tumor, higher concentrations of nanoparticles are needed for IV delivery compared to IP, which is
already localized to the tumor site. These biodistribution
results validate our strategy for targeting TAMs in ovarian tumors via IP injections, and they demonstrate the
reduced off-target delivery due to mannose conjugation
which promotes active macrophage uptake in the ascites
and tumor.
To evaluate therapeutic efficacy of MnNP treatment in
ID8 tumors, we administered treatments on three consecutive days. One of the primary concerns with multiday treatments was the toxicity potentially associated
with nanoparticle injection. However, all treatments
resulted in serum measurements within normal ranges
indicating the safety of consecutive day treatments. This
result is important as this regimen could be necessary
for treating late-stage disease with a minimal timeframe
available for treatment. These results from treating the
late-stage model with therapeutic IκBα-MnNPs were
encouraging because, although tumor burden was not
significantly affected because of the late-stage treatment,
the trend of decreased ascites volume provides positive
signs of a therapeutic effect. The potential for reducing ascites accumulation after only 3 days of treatment
at late stages of disease progression is promising for the
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future of TAM-targeted immunotherapies, especially
as a potential treatment for overcoming chemoresistance. Ascites development is commonly associated with
ovarian cancer (present in over one-third of patients),
is linked to worse disease prognosis, and contributes to
the development of chemoresistance due to the large
population of immunosuppressive cells [18–20]. These
early indications reveal treatment with MnNPs can alter
the tumor microenvironment in ways that may provide
synergy with other approved therapies to produce more
pronounced anti-tumor effects. Also, although tumor
weight did not change, positive anti-tumor effects were
observed in H&E staining of the solid tumor indicating
the MnNPs could reach the tumor and cause some histological changes, even following only 3 days of treatment.
Furthermore, positive effects were seen in the changes
of RNA expression in ascites cells, such as the significant increase in M1 marker CCL3 and the significant
decrease in IL-6. The decrease in IL-6 expression is
important since this cytokine is released by immunosuppressive TAMs and has a direct stimulatory effect on
ovarian tumor cells [68, 69]. Additionally, the observed
increase in IκBα expression in the Scr-MnNP treatment
compared to control indicates the effect of the negative
feedback loop of IκBα production [59]. Consistent with
our other findings, the Scr-MnNP treatment leading to
an increased M1 response would subsequently cause an
increase in IκBα production as the feedback loop in the
macrophages is activated. The decrease in IκBα expression between the Scr-MnNP and IκBα-MnNP groups
reveals the potential mechanism leading to a synergistic
repolarization of TAMs. While both treatments potentially cause M1-induced inflammation, the IκBα-MnNP
treatment prevents the feedback loop of producing
more IκBα from occurring, allowing for a more robust
macrophage repolarization. There were also trends of
increasing CCL3 and TNF-α expression in the tumor
cells, indicating a slight pro-inflammatory effect in the
solid tumors. These results suggest that the IκBα-MnNPs
are altering the TME in the ascites, but at this timepoint
in response to a short-term treatment, the solid tumor
is not significantly altered. These results align with our
observations of ascites volume decreasing after IκBαMnNP treatment but not the tumor weight. Overall,
treatment with IκBα-MnNPs provides benefits in the
context of late-stage disease but will likely need to be
used in combination with other therapies or started earlier in the disease development to produce robust antitumor effects. These encouraging results in a late-stage
model indicate a potential future avenue for evaluating the synergistic effects of combining IκBα-MnNPs
with chemotherapeutics to overcome the chemoresistance often associated with late-stage ovarian tumors.

Glass et al. BMC Cancer

(2022) 22:497

Combination therapies will be necessary for late-stage
tumor treatment since single therapies are unable to fully
overcome the immunosuppressive TME.
The encouraging results in late-stage treatment provided insight into the effects IκBα-MnNPs have on
immune cells in the TME. A second model using TBR5
ovarian tumors was adopted to examine early-stage
treatments in an aggressive model. To combat the more
aggressive tumor model, a biweekly treatment regimen
was implemented. This treatment was also possible since
the mice were not close to humane endpoint at the start
of the treatment. Biodistribution was again examined in
the biweekly model with a comprehensive immune cell
panel to determine the efficiency of specific targeting
to macrophages. These results demonstrated the preferential delivery of MnNPs to the targeted cell populations (macrophages and monocytes) that express the
CD206 mannose receptor. Significant MnNP delivery
to the TAM populations (89% in the ascites and 34% in
the tumors) is essential for altering macrophage phenotype to overcome the immunosuppressive TME. Furthermore, the low uptake in CD45- cells, which includes
tumor cells, is important for preventing off-target delivery of IκBα siRNA and therefore unwanted activation
of NF-κB in cells besides macrophages. There was also
minimal uptake in all other immune cells in the ascites
and tumors, and less than 5% of any immune cell population in the spleen gated positive for MnNP delivery.
These results indicate that the IP delivery is effectively
localizing the MnNP delivery to the peritoneal cavity and
increasing to the biweekly treatment does not increase
the amount of nanoparticle dosage that escapes the peritoneum. Importantly, these results show improvements
over previous studies using a similar NP system loaded
with mRNA that included a targeting moiety, which
resulted in significant off-target delivery to the spleens
even after IP injections [25]. To achieve a macrophagedependent anti-tumor immune response, it is important
to repolarize a large enough population of the TAMs so
that the M1 macrophages can overcome the immunosuppressive TME and increase inflammation and immune
activation while also limiting potential systemic toxicity
due to off-target delivery.
The therapeutic effect of IκBα-MnNP was prevalent in
the TBR5 model. Importantly, increasing to a biweekly
MnNP treatment did not increase toxicity based on AST,
ALT, and BUN levels in the serum. These treatments also
significantly decreased ascites volume, indicating an effect
of the mannosylated carriers themselves, similar to the
results seen in canonical NF-κB activation. The beneficial
effect of mannosylated carriers alone on tumor suppression and polarizing macrophages toward the M1-like phenotype has been previously reported and is therefore not

Page 15 of 19

surprising in this context [25, 70]. In fact, the potential
combination of mannosylated carriers with IκBα siRNA
could combine for a more robust anti-tumor effect. The
tumor weights were not significantly altered in any of the
treatment groups, likely due to low overall tumor burden as seen by the small tumor weights, but there was a
clear trend in decreasing tumor mass in the IκBα-MnNP
treatment. H&E staining of the tumor sections revealed
changes in tumor tissue histology and IF staining for CD8
T cells revealed a clear increase in T cell infiltration in the
IκBα-MnNP treatment. This result is crucial to the future
of developing macrophage-based immunotherapies as
it supports the hypothesis that activating inflammatory
macrophages can also “prime” solid tumors to be more
responsive to T cell-based immunotherapies. This result is
also supported by the significant increase in RNA expression of CXCL9 in the ascites, which is a chemokine produced by M1 macrophages to attract T cells and induce
a Th1 response [71]. The evidence of increased T cell
infiltration supports the potential future combination
of MnNP treatment with immune checkpoint blockades
which necessitate T cell infiltration for functionality.
Increased tumor-infiltrating T cells and significant reduction in ascites volume associated with IκBα-MnNP treatment support the future directions of utilizing MnNPs for
tumor treatments in combination therapies.
Western blot analysis of cells in the ascites revealed
that the IκBα-MnNPs reduced IκBα protein levels, contributing to changes in immune cell composition. This
change was also evidenced by the significant decreases
in IL-6 and Arginase-1 which confirm a shift away from
pro-tumor immune phenotypes. More importantly, there
was a significant increase in TNF-α expression in the
solid tumor. The biweekly treatment enabled MnNPs to
successfully deliver to the TAMs in the solid tumor and
alter immune cell phenotype. The trend in decreasing
tumor weight, though not significant, demonstrated the
effects of IκBα-MnNP delivery to TAMs, altering their
phenotype, and inducing changes in other immune cells
in the TME. The advantages of IP delivery of MnNPs to
treat ovarian tumors are supported by the delivery studies and the therapeutic studies, both of which reveal
nanoparticle penetration into the solid tumor as well as
changes in immune cell phenotype in the tumor.
The addition of the extended treatment model was used
to follow-up the original TBR5 experiment to further
examine IκBα-MnNP therapeutic efficacy. The shorter
treatment revealed positive signs of anti-tumor immunity, so the logical follow-up was to extend treatment
by 1 week (two extra doses). These results immediately
revealed the significant therapeutic benefits of MnNP
delivery with the ascites volume and tumor weight being
significantly reduced in the treatments. Similar to the
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previous cohorts, we once again saw therapeutic effects of
the mannoslyated carrier alone with a more pronounced
effect in the IκBα-MnNP. Furthermore, this study examined in detail the immune cell populations comprising
the ascites and tumor and revealed several significant
findings. The significant shift in TAMs from an M2 to
M1 phenotype in vivo indicates that the IκBα-MnNPs
recapitulate the results seen in vitro and can produce
the inflammatory microenvironment observed through
PCR results in the previous studies. This effect was seen
in both the ascites and the tumors which again validates
the biweekly IP injection as a therapeutically effective
treatment strategy. Furthermore, these results confirm
the effects of Scr-MnNPs in shift TAMs away from an
M2 phenotype, and the synergistic effect of loading with
IκBα siRNA is evidenced by the significant decrease in the
percent of CD206+ TAMs in the IκBα-MnNP treatment
compared to the Scr-MnNP treatment. Also, in line with
the previous observations of increased CD8 T cell infiltration, analysis of CD8 T cell populations revealed a trend
of increased infiltration in IκBα-MnNP treated mice. Further increases in inflammatory monocyte and NK cell
populations confirm the ability of macrophage repolarization to recruit and effect other immune cell populations
to lead to anti-tumor immune responses.
Overall, these studies indicate a therapeutic benefit
from IκBα-MnNP treatment in ovarian tumors. While
the late-stage treatment of ID8 tumors did not significantly alter tumor progression, there were signs of
changes in the immune cell composition and a trend in
decreasing ascites accumulation, indicating some positive responses. Future studies in this model may examine
increasing the MnNP dosage or combining MnNP treatment with currently approved chemotherapies. Many
patients develop chemoresistance in late-stage EOC and
this phenomenon is often exacerbated by the buildup of
ascites [19, 20]. By implementing IκBα-MnNP treatment
initially to reduce ascites accumulation, we could examine the potential effects of MnNPs to restore chemotherapy responsiveness in late-stage ovarian tumors.
Similarly, the positive therapeutic effects seen in the
early-stage treatment of the aggressive TBR5 model, in
terms of tumor progression and immune cell composition, provide context for future directions in combining
MnNP treatments with T cell-targeted immunotherapies. Many of the current T cell-based therapies are not
as effective in treating solid tumors due to low T cell infiltration and high levels of immunosuppressive cytokines.
Targeting TAMs to produce pro-inflammatory cytokines,
such as IFN-γ and TNF-α, can promote an immunefavorable microenvironment while also producing T cellspecific chemokines, such as CXCL9, to recruit T cells to
the tumor. The logical next step in this research will be to
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examine combination treatments with ICBs, such as antiPD-1 s, to potentially produce a more robust immune
response and develop immunological memory to prevent subsequent recurrence. The results of this study
demonstrated positive therapeutic results but have also
informed our future directions for developing therapies
to treat ovarian cancer in patients.

Conclusions
This work demonstrates the efficacy of MnNPs in inducing TAM-mediated anti-tumor immunity in mouse
models of ovarian cancer. Delivery of IκBα siRNA to
NGL-BMDMs activated canonical NF-κB, indicating
repolarization of the macrophages toward an inflammatory M1-like phenotype. Biodistribution studies in two
different tumor models revealed preferential MnNP association with TAM and myeloid cell populations only in
the ascites and solid tumors with minimal off-target delivery to other immune cells and negligible uptake in any
cells in the spleens. These results supported the use of IP
injections to provide localized delivery to the TME. The
delivery of MnNPs to macrophages in the ascites led to a
slight decrease in ascites buildup in the late-stage model,
but a substantial decrease in the aggressive TBR5 model.
The positive effect of mannosylated carriers on preventing ascites development in the aggressive TBR5 model
indicates a potential for synergistic effects of IκBα siRNA
with MnNPs. While the late-stage treatment of ID8
tumors did not significantly alter tumor progression, there
were noticeable differences in RNA expression of various M1- and M2-associated markers, indicating beneficial immunostimulatory changes in the TME after MnNP
treatment. In the more aggressive TBR5 model, the IκBαMnNP treatment led to slight decreases in tumor weight,
but also was associated with larger numbers of infiltrating
CD8 T cells. The increase in tumor-associated T cells is
highly encouraging for future studies involving combination treatments with immune checkpoint blockades
which rely on the presence of T cells in the tumors for
anti-cancer toxicity. Additionally, we demonstrated that
an extended treatment of MnNPs in the TBR5 model
significantly suppressed ascites accumulation and tumor
development while also altering the immune cell composition in the TME. These results further support the
hypothesis that activating macrophages can transform the
TME into a pro-inflammatory niche which will support
ICB therapies. Importantly, this study shines a light on
the potential for IP administered therapies that can influence tumors in the peritoneal cavity through modulation
of cells in the ascites. Overall, this work highlights the use
of MnNPs in IP treatment of ovarian cancer and provides
a pathway forward for enhancing the current treatment
paradigm in patients with a highly deadly disease.
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